Filing Details

Accession Number:
0001209191-19-030040
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-15 16:42:25
Reporting Period:
2019-05-13
Accepted Time:
2019-05-15 16:42:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1628738 Audentes Therapeutics Inc. BOLD Biological Products, (No Disgnostic Substances) (2836) 461606174
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1679129 Suyash Prasad C/O Audentes Therapeutics, Inc.
600 California Street, 17Th Floor
San Francisco CA 94108
Senior Vp & Chief Med Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-13 10,000 $0.79 28,236 No 4 M Direct
Common Stock Disposition 2019-05-13 9,946 $36.98 18,290 No 4 S Direct
Common Stock Disposition 2019-05-13 54 $37.72 18,236 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-05-13 10,000 $0.00 10,000 $0.79
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,870 2024-02-18 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
  2. Represents the weighted average sale price. The lowest price at which shares were sold was $36.61 and the highest price at which shares were sold was $37.46. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events.